Improved myocardial perfusion in stable angina pectoris by oral lumbrokinase: a pilot study.
OBJECTIVE
A novel antithrombotic agent, lumbrokinase, was evaluated in this pilot study for its efficacy in the treatment of symptomatic stable angina.


METHODS
This was a single-armed cohort study.


METHODS
The study was conducted at the National Cardiovascular Center, Harapan Kita, Jakarta, Indonesia.


METHODS
The study comprised 10 patients who had coronary artery disease and stable angina and who consented to the trial.


METHODS
Patients were treated with oral lumbrokinase for 30 consecutive days in addition to their standard medical therapy.


METHODS
Stress technetium-99m sestamibi myocardial perfusion imaging (MPI) was performed before and at the conclusion of the active treatment period. The degree and extent of inducible ischemia observed on the myocardial perfusion images were evaluated using the previously validated semiquantitative indices (Summed Stress Score and Summed Difference Score).


RESULTS
Following active treatment, the mean Summed Stress Score and Summed Difference Score deceased by 39% and 37%, respectively. The anginal symptom was ameliorated in 6 of 10 patients. No adverse reaction including major or minor bleeding was observed.


CONCLUSIONS
This paper represents the first description of the use of oral lumbrokinase in the treatment of chronic coronary artery disease with objective assessment using MPI. Oral lumbrokinase improves regional myocardial perfusion in patients with stable angina.
Kasim
Manoefris
M
Department of Cardiology and Vascular Medicine, Harapan Kita National Cardiovascular Center, and Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Kiat
Andrew Alexander
AA
Rohman
Mohammad Saifur
MS
Hanifah
Yasmina
Y
Kiat
Hosen
H
D000284:Administration, Oral; D000368:Aged; D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy*; D000818:Animals; D015331:Cohort Studies; D003324:Coronary Artery Disease / Q000188:drug therapy*; D010450:Endopeptidases / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D055414:Myocardial Perfusion Imaging / Q000379:methods; D009835:Oligochaeta; D010865:Pilot Projects; D055502:Secondary Prevention / Q000379:methods; D017256:Technetium Tc 99m Sestamibi
D005343:Fibrinolytic Agents; D017256:Technetium Tc 99m Sestamibi; D010450:Endopeptidases; C083421:lumbrokinase